Peptide macrocycle decoys against COVID-19 viral spike protein [Added supplement: COVID-19 Variant Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 172633, 175523

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $162,453.22
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    University of British Columbia Chemistry
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Peptides are potent, easy-to-synthesize, and synthetically accessible molecules that can specifically interact with pathogens. Peptides have been used to treat diabetes, neuropathic pain, cancer, and HIV. As chemists we have very recently invented news ways to make peptides both more potent as well as fluorescent in order to see where they go and how they act. We are poised to interface our technology with molecular modelling to synthesize peptides that will intercept the virus before it can enter a cell. These peptides can be injected or nasally delivered for therapy and can be used prior to vaccine development or in cases where certain patients cannot be vaccinated.